Abstract
Abstract Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir (TDF/FTC) can reduce HIV infection risk by 92% in people at high risk for HIV. TDF/FTC was approved for HIV PrEP by the Food and Drug Administration in 2012. Primary care nurse practitioners (NPs) have not embraced this tool for the prevention of new HIV infection. A number of barriers exist that may prevent primary care NPs from prescribing HIV PrEP for patients in need. This article clarifies current recommendations for HIV PrEP and provides practical guidance for primary care NPs to incorporate this tool into their routine practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
